APELLIS PHARMACT.DL-0001
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy… Read more
Market Cap & Net Worth: APELLIS PHARMACT.DL-0001 (1JK)
APELLIS PHARMACT.DL-0001 (F:1JK) has a market capitalization of $2.03 Billion (€1.98 Billion) as of March 19, 2026. Listed on the F stock exchange, this Germany-based company holds position #5972 globally and #628 in its home market, demonstrating a -4.48% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying APELLIS PHARMACT.DL-0001's stock price €15.66 by its total outstanding shares 126525218 (126.53 Million).
APELLIS PHARMACT.DL-0001 Market Cap History: 2019 to 2026
APELLIS PHARMACT.DL-0001's market capitalization history from 2019 to 2026. Data shows change from $3.31 Billion to $2.04 Billion (-5.09% CAGR).
APELLIS PHARMACT.DL-0001 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how APELLIS PHARMACT.DL-0001's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of 1JK by Market Capitalization
Companies near APELLIS PHARMACT.DL-0001 in the global market cap rankings as of March 19, 2026.
Key companies related to APELLIS PHARMACT.DL-0001 by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
APELLIS PHARMACT.DL-0001 Historical Marketcap From 2019 to 2026
Between 2019 and today, APELLIS PHARMACT.DL-0001's market cap moved from $3.31 Billion to $ 2.04 Billion, with a yearly change of -5.09%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €2.04 Billion | -23.99% |
| 2025 | €2.68 Billion | -32.36% |
| 2024 | €3.97 Billion | -45.93% |
| 2023 | €7.34 Billion | +19.09% |
| 2022 | €6.16 Billion | +14.60% |
| 2021 | €5.38 Billion | -6.76% |
| 2020 | €5.77 Billion | +74.29% |
| 2019 | €3.31 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of APELLIS PHARMACT.DL-0001 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $2.03 Billion USD |
| MoneyControl | $2.03 Billion USD |
| MarketWatch | $2.03 Billion USD |
| marketcap.company | $2.03 Billion USD |
| Reuters | $2.03 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.